-
Something wrong with this record ?
Coupling between beta band and high frequency oscillations as a clinically useful biomarker for DBS
M. Bočková, M. Lamoš, J. Chrastina, P. Daniel, S. Kupcová, I. Říha, L. Šmahovská, M. Baláž, I. Rektor
Status not-indexed Language English Country United States
Document type Journal Article
Grant support
21-25953S
Grantová Agentura České Republiky (Grant Agency of the Czech Republic)
21-25953S
Grantová Agentura České Republiky (Grant Agency of the Czech Republic)
21-25953S
Grantová Agentura České Republiky (Grant Agency of the Czech Republic)
21-25953S
Grantová Agentura České Republiky (Grant Agency of the Czech Republic)
NLK
Directory of Open Access Journals
from 2015
Nature Open Access
from 2015-12-01
PubMed Central
from 2015
Europe PubMed Central
from 2015
ProQuest Central
from 2015-04-01
Open Access Digital Library
from 2015-04-22
Open Access Digital Library
from 2015-01-01
Health & Medicine (ProQuest)
from 2015-04-01
ROAD: Directory of Open Access Scholarly Resources
from 2015
Springer Nature OA/Free Journals
from 2015-12-01
- Publication type
- Journal Article MeSH
Beta hypersynchrony was recently introduced into clinical practice in Parkinson's disease (PD) to identify the best stimulation contacts and for adaptive deep brain stimulation (aDBS) sensing. However, many other oscillopathies accompany the disease, and beta power sensing may not be optimal for all patients. The aim of this work was to study the potential clinical usefulness of beta power phase-amplitude coupling (PAC) with high frequency oscillations (HFOs). Subthalamic nucleus (STN) local field potentials (LFPs) from externalized DBS electrodes were recorded and analyzed in PD patients (n = 19). Beta power and HFOs were evaluated in a resting-state condition; PAC was then studied and compared with the electrode contact positions, structural connectivity, and medication state. Beta-HFO PAC (mainly in the 200-500 Hz range) was observed in all subjects. PAC was detectable more specifically in the motor part of the STN compared to beta power and HFOs. Moreover, the presence of PAC better corresponds to the stimulation setup based on the clinical effect. PAC is also sensitive to the laterality of symptoms and dopaminergic therapy, where the greater PAC cluster reflects the more affected side and medication "off" state. Coupling between beta power and HFOs is known to be a correlate of the PD "off" state. Beta-HFO PAC seems to be more sensitive than beta power itself and could be more helpful in the selection of the best clinical stimulation contact and probably also as a potential future input signal for aDBS.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24005742
- 003
- CZ-PrNML
- 005
- 20240412131031.0
- 007
- ta
- 008
- 240405s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41531-024-00656-8 $2 doi
- 035 __
- $a (PubMed)38383550
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Bočková, Martina $u Brain and Mind Research Program, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u First Department of Neurology, Masaryk University School of Medicine, St. Anne's Hospital, Brno, Czech Republic $1 https://orcid.org/0000000326919122
- 245 10
- $a Coupling between beta band and high frequency oscillations as a clinically useful biomarker for DBS / $c M. Bočková, M. Lamoš, J. Chrastina, P. Daniel, S. Kupcová, I. Říha, L. Šmahovská, M. Baláž, I. Rektor
- 520 9_
- $a Beta hypersynchrony was recently introduced into clinical practice in Parkinson's disease (PD) to identify the best stimulation contacts and for adaptive deep brain stimulation (aDBS) sensing. However, many other oscillopathies accompany the disease, and beta power sensing may not be optimal for all patients. The aim of this work was to study the potential clinical usefulness of beta power phase-amplitude coupling (PAC) with high frequency oscillations (HFOs). Subthalamic nucleus (STN) local field potentials (LFPs) from externalized DBS electrodes were recorded and analyzed in PD patients (n = 19). Beta power and HFOs were evaluated in a resting-state condition; PAC was then studied and compared with the electrode contact positions, structural connectivity, and medication state. Beta-HFO PAC (mainly in the 200-500 Hz range) was observed in all subjects. PAC was detectable more specifically in the motor part of the STN compared to beta power and HFOs. Moreover, the presence of PAC better corresponds to the stimulation setup based on the clinical effect. PAC is also sensitive to the laterality of symptoms and dopaminergic therapy, where the greater PAC cluster reflects the more affected side and medication "off" state. Coupling between beta power and HFOs is known to be a correlate of the PD "off" state. Beta-HFO PAC seems to be more sensitive than beta power itself and could be more helpful in the selection of the best clinical stimulation contact and probably also as a potential future input signal for aDBS.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Lamoš, Martin $u Brain and Mind Research Program, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000312764342
- 700 1_
- $a Chrastina, Jan $u Department of Neurosurgery, Masaryk University School of Medicine, St. Anne's Hospital, Brno, Czech Republic
- 700 1_
- $a Daniel, Pavel $u Brain and Mind Research Program, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u First Department of Neurology, Masaryk University School of Medicine, St. Anne's Hospital, Brno, Czech Republic
- 700 1_
- $a Kupcová, Silvia $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Říha, Ivo $u Department of Neurosurgery, Masaryk University School of Medicine, St. Anne's Hospital, Brno, Czech Republic
- 700 1_
- $a Šmahovská, Lucia $u First Department of Neurology, Masaryk University School of Medicine, St. Anne's Hospital, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Baláž, Marek $u Brain and Mind Research Program, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u First Department of Neurology, Masaryk University School of Medicine, St. Anne's Hospital, Brno, Czech Republic
- 700 1_
- $a Rektor, Ivan $u Brain and Mind Research Program, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. ivan.rektor@fnusa.cz $u First Department of Neurology, Masaryk University School of Medicine, St. Anne's Hospital, Brno, Czech Republic. ivan.rektor@fnusa.cz $1 https://orcid.org/0000000296357404 $7 nlk19990073773
- 773 0_
- $w MED00208625 $t NPJ Parkinson's disease $x 2373-8057 $g Roč. 10, č. 1 (2024), s. 40
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38383550 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240405 $b ABA008
- 991 __
- $a 20240412131024 $b ABA008
- 999 __
- $a ok $b bmc $g 2076009 $s 1215504
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 10 $c 1 $d 40 $e 20240221 $i 2373-8057 $m NPJ Parkinson's disease $n NPJ Parkinsons Dis $x MED00208625
- GRA __
- $a 21-25953S $p Grantová Agentura České Republiky (Grant Agency of the Czech Republic)
- GRA __
- $a 21-25953S $p Grantová Agentura České Republiky (Grant Agency of the Czech Republic)
- GRA __
- $a 21-25953S $p Grantová Agentura České Republiky (Grant Agency of the Czech Republic)
- GRA __
- $a 21-25953S $p Grantová Agentura České Republiky (Grant Agency of the Czech Republic)
- LZP __
- $a Pubmed-20240405